黄金城集团

目录产品 » SARS-CoV-2 (Omicron) Neutralizing Antibody Standard

SARS-CoV-2 (Omicron) Neutralizing Antibody Standard

The new SARS-CoV-2 variant Omicron (B.1.1.529) was first identified in South Africa and classified as a variant of concern (VOC). Following the quick rise of the Delta variant, Omicron’s emergence is concern of scientists due to the impressive number of mutations within the Spike protein (~ 30 mutations). The increased number of mutations in Spike’s receptor-binding domain (RBD) may affect this variant interaction with the ACE2 or neutralizing antibodies. This product is intended for the calibration of SARS-CoV-2 (Omicron) neutralizing antibodies in the materials or samples. It can be used in the assessment and development of assays for the detection and quantitation of SARS-CoV-2 (Omicron) neutralizing antibodies.
询价
V80402-0.1

Specificity The product is specific for SARS-CoV-2 RBD domain
Unitage The unitage of this product has been defined as an arbitrary unit of 800,000U/ml.
Isotype IgG
Clonality Cocktail
返回

Purification Protein A/G affinity column
Formulation 0.2 μm filtered PBS, pH 7.2.
Storage For long term storage, aliquot and store at -25°C~-15°C or below. Avoid repeated freezing and thawing cycles.
Note GenScript can customize this product per customer's request including product size, buffer components, etc.
返回

Items Recommended Usage
Surrogate Virus Neutralization Test (sVNT) 10 U/ml - 1,200 U/ml
Pseudovirus Neutralization Test (pVNT) User-optimized
Plaque Reduction Neutralization Test (PRNT) User-optimized
Other applications User-optimized
返回

SARS-CoV-2 (Omicron) Neutralizing Antibody Standard

»

<
>

Target Background The new SARS-CoV-2 variant Omicron (B.1.1.529) was first identified in South Africa and classified as a variant of concern (VOC). Following the quick rise of the Delta variant, Omicron’s emergence is concern of scientists due to the impressive number of mutations within the Spike protein (~ 30 mutations). The increased number of mutations in Spike’s receptor-binding domain (RBD) may affect this variant interaction with the ACE2 or neutralizing antibodies. This product is intended for the calibration of SARS-CoV-2 (Omicron) neutralizing antibodies in the materials or samples. It can be used in the assessment and development of assays for the detection and quantitation of SARS-CoV-2 (Omicron) neutralizing antibodies.
返回

 For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.